STOCK TITAN

Baxter International (BAX) Financials

BAX NYSE
FY2025 annual
Revenue $11.2B +5.7% YoY
Net Income -$957.0M n/m YoY
EPS (Diluted) -$1.87 n/m YoY
Free Cash Flow $332.0M -42.1% YoY
Market Cap $13.3B as of Nov 17, 2026
Price / Sales 1.1x on $11.6B revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 2.0x on $6.5B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BAX SEC filings page.

Baxter International Inc. (BAX) reported $11.2B in revenue for fiscal year 2025, up 5.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BAX FY2025

Revenue growth is being overwhelmed by rising production costs, while reinvestment consumes more cash and the balance sheet contracts.

Revenue grew 8.5% from FY2023 to FY2025, but cost of revenue grew 26.7%, so the business is adding sales without retaining comparable gross profit. This margin deterioration indicates worsening cost absorption rather than operating leverage.

Capital expenditures consumed 60.7% of operating cash flow in FY2025 versus 25.0% in FY2023, so a larger portion of internally generated cash is being absorbed by reinvestment. That helps explain why free cash flow fell 74.3% across the same span, even as revenue increased.

From FY2023 to FY2025, total assets fell 29.1% while total equity fell 27.1%; the balance sheet is shrinking, but not through a proportionate strengthening of the owners’ cushion. Current ratio improved to 2.3x in FY2025 alongside a smaller short-term liability base, while inventory rose 16.4% over the span—an important working-capital countertrend.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 36 / 100
Financial Health Score 36/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Baxter International Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
25

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Baxter International Inc. scores 25/100 on it among other operating companies.

Growth
45

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Baxter International Inc. scores 45/100 on it among other operating companies.

Leverage
4

Baxter International Inc.'s net debt of $7.5B, being $9.5B of long-term debt less $2.0B of cash, came to 11.15 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Baxter International Inc. scores 4/100 among other operating companies measured the same way.

Liquidity
67

Baxter International Inc. held $2.31 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 2.31. Liquidity ranks operating companies on that ratio, and Baxter International Inc. scores 67/100 among other operating companies.

Cash Flow
49

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Baxter International Inc. scores 49/100 on it among other operating companies.

Returns
24

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Baxter International Inc. scores 24/100 on it among other operating companies.

Altman Z-Score Grey Zone
2.27

Baxter International Inc. scores 2.27, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from retained earnings of $13.7B against total assets of $20.1B. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
4/9

Baxter International Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Mixed
N/A

Baxter International Inc. reported a net loss of $957.0M while generating $845.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Baxter International Inc. reported an operating loss of $308.0M against $290.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$3.0B
YoY+5.0%
QoQ+0.5%
5Y CAGR-1.6%
10Y CAGR+1.5%

Baxter International Inc. generated $3.0B in revenue in Q3 2026. This represents an increase of 5.0% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

EBITDA
$464.0M
YoY+13.4%
QoQ+1.8%

Baxter International Inc.'s EBITDA was $464.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.4% from the same quarter a year earlier. Against the prior quarter it is up 1.8%.

Net Income
$294.0M
YoYn/m
QoQ+133.3%
5Y CAGR-8.2%
10Y CAGR+8.5%

Baxter International Inc. reported $294.0M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 133.3%.

EPS (Diluted)
$0.57
YoYn/m
QoQ+137.5%
5Y CAGR-8.5%
10Y CAGR+9.0%

Baxter International Inc. earned $0.57 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 137.5%.

Cash & Balance Sheet

Cash & Debt
$2.0B
YoY+14.4%
QoQ-8.1%
5Y CAGR-9.5%
10Y CAGR-2.7%

Baxter International Inc. held $2.0B in cash as of Q3 2026; no long-term debt figure is on record for that period.

Dividends Per Share
$0.01
YoY-94.1%
QoQ0.0%
5Y CAGR-48.6%
10Y CAGR-22.6%

Baxter International Inc. paid $0.01 per share in dividends in Q3 2026. This represents a decrease of 94.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding
517M
YoY+0.6%
QoQ+0.1%
5Y CAGR+0.7%

Baxter International Inc. had 517M shares outstanding in Q3 2026. This represents an increase of 0.6% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Free Cash Flow

Not reported for Q3 2026.

Margins & Returns

Gross Margin
33.4%
YoY-0.1pp
QoQ-1.5pp
5Y change-7.5pp
10Y change-8.5pp

Baxter International Inc.'s gross margin was 33.4% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.5 percentage points.

Operating Margin
7.6%
YoY+1.5pp
QoQ+0.2pp

Baxter International Inc.'s operating margin was 7.6% in Q3 2026, reflecting core business profitability. This is up 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Net Margin
9.9%
YoY+11.5pp
QoQ+5.6pp
5Y change-4.1pp
10Y change+4.8pp

Baxter International Inc.'s net profit margin was 9.9% in Q3 2026, showing the share of revenue converted to profit. This is up 11.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.6 percentage points.

Return on Equity
4.5%
YoY+5.2pp
QoQ+2.5pp
5Y change-0.6pp
10Y change+3.0pp

Baxter International Inc.'s quarterly ROE was 4.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.5 percentage points.

Capital Allocation

R&D Spending
$125.0M
YoY+5.9%
QoQ-3.1%

Baxter International Inc. invested $125.0M in research and development in Q3 2026. This represents an increase of 5.9% from the same quarter a year earlier. Against the prior quarter it is down 3.1%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

BAX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BAX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$3.0B+5.0%$3.0B+5.3%$2.7B+2.9%$3.0B+8.0%$2.8B+5.0%$2.8B+4.3%$2.6B+5.4%$2.8B+0.9%
Cost of Revenue$2.0B+5.1%$1.9B+6.0%$1.8B+2.6%$2.4B$1.9B+13.1%$1.8B+9.4%$1.8B+15.4%N/A
Gross Profit$994.0M+4.6%$1.0B+4.1%$891.0M+3.5%$577.0M-39.8%$950.0M-8.0%$991.0M-3.9%$861.0M-10.4%$959.0M-12.8%
R&D Expenses$125.0M+5.9%$129.0M-3.7%$139.0M-0.7%$126.0M$118.0M-8.5%$134.0M+3.1%$140.0M+16.7%N/A
SG&A Expenses$730.0M+3.1%$735.0M+2.4%$728.0M+3.6%$761.0M$708.0M-6.1%$718.0M-0.7%$703.0M-3.6%N/A
Operating Income$225.0M+30.8%$217.0M+13.6%$66.0M+13.8%-$729.0M$172.0M+11.0%$191.0M+6.7%$58.0M-49.6%N/A
EBITDA$464.0M+13.4%$456.0M+1.8%$303.0M-0.7%-$489.0M$409.0M0.0%$448.0M+10.3%$305.0M-21.0%N/A
Interest Expense-$13.0Mn/m-$13.0Mn/m-$12.0Mn/m$331.0M-$10.0Mn/m-$14.0M-113.5%-$17.0M-116.5%N/A
Income Tax$119.0M-30.8%$23.0M+109.1%$11.0Mn/m$279.0M$172.0M+2050.0%$11.0M-50.0%-$67.0M-267.5%N/A
Net Income$294.0Mn/m$126.0M+38.5%-$15.0M-111.9%-$1.1Bn/m-$46.0M-132.9%$91.0Mn/m$126.0M+240.5%-$512.0M-309.0%
EPS (Basic)$0.57n/m$0.24+33.3%-$0.03-112.0%-$2.20n/m-$0.09-133.3%$0.18n/m$0.25+257.1%-$1.00-308.3%
EPS (Diluted)$0.57n/m$0.24+33.3%-$0.03-112.0%-$2.20n/m-$0.09-133.3%$0.18n/m$0.25+257.1%-$1.00-308.3%
Diluted Shares (Avg)520M+1.2%518M+0.8%515M+0.2%N/A514M+0.4%514M+0.6%514M+0.8%N/A

BAX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BAX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$19.4B-7.8%$19.8B-6.0%$19.8B-6.8%$20.1B-22.2%$21.1B-21.0%$21.0B-20.0%$21.3B-23.3%$25.8B-8.8%
Current Assets$6.8B-1.5%$7.0B+3.6%$6.8B-2.7%$6.9B-22.4%$6.9B-21.8%$6.7B-21.5%$7.0B-25.2%$8.9B-7.8%
Cash & Equivalents$2.0B+14.4%$2.1B+27.5%$2.0B-12.1%$2.0B+11.5%$1.7B+21.5%$1.7B+7.1%$2.3B-18.8%$1.8B-42.7%
Short-Term InvestmentsN/AN/AN/AN/A$0n/m$0n/m$0n/mN/A
Inventory$2.3B-6.5%$2.3B-5.2%$2.3B+6.7%$2.2B+9.1%$2.5B+17.0%$2.4B-20.1%$2.2B-27.4%$2.0B+6.7%
Accounts Receivable$1.8B+0.3%$1.9B+4.7%$1.7B+3.2%$1.9B+10.8%$1.8B+2.8%$1.8B-32.8%$1.6B-34.7%$1.7B-2.3%
Long-Term InvestmentsN/AN/AN/A$103.0M-5.5%$0n/m$0n/m$0n/m$109.0M-19.9%
Goodwill$4.9B-9.8%$4.9B-9.4%$4.9B-8.2%$4.9B-6.6%$5.4B-6.6%$5.4B-10.1%$5.3B-17.0%$5.3B-8.9%
Total Liabilities$12.9B-6.6%$13.6B-1.0%$13.8B-2.9%$14.0B-25.6%$13.9B-26.1%$13.8B-26.1%$14.3B-27.1%$18.8B-5.3%
Current Liabilities$3.8B+0.9%$3.6B+22.2%$3.7B+6.1%$3.0B-54.4%$3.8B-39.1%$2.9B-52.1%$3.5B-45.3%$6.5B+0.1%
Non-Current Liabilities$9.1B-9.4%$10.0B-7.3%$10.1B-5.9%$11.0B-10.3%$10.1B-19.6%$10.8B-13.3%$10.8B-18.3%$12.2B-8.0%
Long-Term DebtN/AN/AN/A$9.5B-8.7%N/AN/AN/A$10.4B-6.4%
Total Equity$6.5B-10.2%$6.2B-15.2%$6.0B-14.7%$6.1B-12.0%$7.2B-8.0%$7.3B-4.2%$7.1B-13.4%$7.0B-17.1%
Retained Earnings$14.1B-5.0%$13.8B-7.8%$13.7B-8.6%$13.7B-8.2%$14.8B-4.5%$15.0B-3.7%$15.0B-6.5%$14.9B-7.4%

BAX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BAX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$558.0M+135.4%$285.0M+31.3%$213.0Mn/m$584.0M+19.7%$237.0M-6.3%$217.0M+88.7%-$193.0M-218.4%$488.0M-8.1%
Depreciation & Amortization$239.0M+0.8%$239.0M-7.0%$237.0M-4.0%$240.0M-2.0%$237.0M-6.7%$257.0M+13.2%$247.0M-8.9%$245.0M-7.2%
Stock-Based CompensationN/AN/A$10.0M0.0%N/AN/AN/A$10.0M-41.2%N/A
Investing Cash Flow-$110.0Mn/m-$117.0Mn/m-$133.0M-104.1%-$198.0Mn/m-$111.0Mn/m-$115.0Mn/m$3.3Bn/m-$205.0Mn/m
Financing Cash Flow-$620.0Mn/m-$31.0Mn/m-$11.0Mn/m-$147.0M-204.3%-$81.0Mn/m-$762.0Mn/m-$3.2Bn/m$141.0Mn/m
Dividends Paid$5.0M-94.3%$5.0M-94.3%$5.0M-94.3%$87.0M-40.8%$87.0M-41.2%$87.0M-41.2%$87.0M-40.8%$147.0M0.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Share Buybacks.

BAX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BAX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin33.4%-0.1pp34.9%-0.4pp33.0%+0.2pp19.4%-15.4pp33.5%-4.8pp35.3%-3.0pp32.8%-5.8pp34.8%-5.5pp
Operating Margin7.6%+1.5pp7.3%+0.5pp2.4%+0.2pp-24.5%6.1%+0.3pp6.8%+0.2pp2.2%-2.4ppN/A
Net Margin9.9%+11.5pp4.3%+1.0pp-0.6%-5.4pp-37.9%-19.3pp-1.6%-6.8pp3.2%+14.9pp4.8%+3.3pp-18.6%-27.6pp
Return on Equity4.5%+5.2pp2.0%+0.8pp-0.3%-2.0pp-18.4%-11.1pp-0.6%-2.4pp1.2%+5.3pp1.8%+1.3pp-7.3%-10.3pp
Return on Assets1.5%+1.7pp0.6%+0.2pp-0.1%-0.7pp-5.6%-3.6pp-0.2%-0.7pp0.4%+1.6pp0.6%+0.5pp-2.0%-2.9pp
Current Ratio1.790.0x1.95-0.4x1.85-0.2x2.31+1.0x1.84+0.4x2.30+0.9x2.02+0.5x1.36-0.1x
Debt-to-EquityN/AN/AN/A1.55+0.1xN/AN/AN/A1.49+0.2x
Liabilities-to-Equity1.99+0.1x2.19+0.3x2.29+0.3x2.28-0.4x1.91-0.5x1.88-0.6x2.01-0.4x2.69+0.3x
Asset Turnover0.150.0x0.150.0x0.140.0x0.150.0x0.130.0x0.130.0x0.120.0x0.110.0x

Not reported in any period shown, so not listed: FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Baxter International Inc. BAX FY2025 $11.2B -$957.0M -8.5% $13.3B 36/100
Solventum Corporation SOLV FY2025 $8.3B $1.6B 18.7% $14.6B 52/100
Align Technology Inc ALGN FY2025 $4.0B $410.4M 10.2% $11.5B 59/100
The Cooper Companies, Inc. COO FY2025 $4.1B $374.9M 9.2% $11.5B 60/100
Repligen Corp RGEN FY2025 $738.3M $48.9M 6.6% $10.4B 65/100
Avantor, Inc. AVTR FY2025 $6.6B -$530.2M -8.1% $10.3B 37/100

Frequently Asked Questions

Baxter International Inc. (BAX) reported $11.2B in total revenue for fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Baxter International Inc. (BAX) revenue grew by 5.7% year-over-year, from $10.6B to $11.2B in fiscal year 2025.

No, Baxter International Inc. (BAX) reported a net loss of $957.0M in fiscal year 2025, with a net profit margin of -8.5%.

Baxter International Inc. (BAX) reported diluted earnings per share of -$1.87 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Baxter International Inc. (BAX) had EBITDA of $673.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Baxter International Inc. (BAX) had $2.0B in cash and equivalents against $9.5B in long-term debt.

Baxter International Inc. (BAX) had a gross margin of 30.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Baxter International Inc. (BAX) had an operating margin of -2.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Baxter International Inc. (BAX) had a net profit margin of -8.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Baxter International Inc. (BAX) paid $0.52 per share in dividends during fiscal year 2025.

Baxter International Inc. (BAX) has a return on equity of -15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Baxter International Inc. (BAX) generated $332.0M in free cash flow during fiscal year 2025. This represents a -42.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Baxter International Inc. (BAX) generated $845.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Baxter International Inc. (BAX) had $20.1B in total assets as of fiscal year 2025, including both current and long-term assets.

Baxter International Inc. (BAX) invested $513.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Baxter International Inc. (BAX) invested $518.0M in research and development during fiscal year 2025.

Baxter International Inc. (BAX) had 514M shares outstanding as of fiscal year 2025.

Baxter International Inc. (BAX) had a current ratio of 2.31 as of fiscal year 2025, which is generally considered healthy.

Baxter International Inc. (BAX) had a debt-to-equity ratio of 1.55 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Baxter International Inc. (BAX) had a liabilities-to-equity ratio of 2.28 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Baxter International Inc. (BAX) had a return on assets of -4.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Baxter International Inc. (BAX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $13.3B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Baxter International Inc. (BAX) trades at 1.1x sales, its market capitalization divided by $11.6B revenue, trailing 12 months to September 30, 2026. The market capitalization is $13.3B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Baxter International Inc. (BAX) has an Altman Z-Score of 2.27, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Baxter International Inc. (BAX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Baxter International Inc. (BAX) reported a net loss of $957.0M while generating $845.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Baxter International Inc. (BAX) reported an operating loss of $308.0M against $290.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Baxter International Inc. (BAX) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top